Holen Sie sich die Stockscreener-App
1.355
5.98%
-0.085
Schlusskurs vom Vortag:
$1.44
Offen:
$1.4
24-Stunden-Volumen:
705.80K
Relative Volume:
0.96
Marktkapitalisierung:
$97.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.2985
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
-20.82%
1M Leistung:
-15.91%
6M Leistung:
-6.63%
1J Leistung:
-63.70%
1-Tages-Spanne:
$1.34
$1.43
1-Wochen-Bereich:
$1.34
$1.69
52-Wochen-Spanne:
$1.01
$4.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Vergleichen Sie ZNTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.35 | 103.88M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.22 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.22 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.59 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Is Zentalis Pharmaceuticals Inc. stock in correction or buying zoneMarket Sentiment Summary & Precise Swing Trade Alerts - newser.com
Why Zentalis Pharmaceuticals Inc. stock remains undervalued2025 Market Trends & Community Consensus Stock Picks - newser.com
Why Zentalis Pharmaceuticals Inc. stock is in analyst buy zone2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
Is Zentalis Pharmaceuticals Inc. forming a bottoming baseJuly 2025 Final Week & Free Community Consensus Stock Picks - newser.com
What indicators show strength in Zentalis Pharmaceuticals Inc.Market Risk Analysis & Reliable Price Action Trade Plans - newser.com
Why analysts upgrade Zentalis Pharmaceuticals Inc. stock2025 Investor Takeaways & AI Driven Price Forecasts - newser.com
How geopolitical tensions affect Zentalis Pharmaceuticals Inc. stockChart Signals & Safe Entry Point Alerts - newser.com
Relative strength of Zentalis Pharmaceuticals Inc. in sector analysisJuly 2025 Trends & AI Based Buy/Sell Signal Reports - newser.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis (Nasdaq: ZNTL) awards 17,000 inducement options to new employee - Stock Titan
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Zentalis (NASDAQ: ZNTL) to participate in Guggenheim and Stifel healthcare conferences - Stock Titan
Can Zentalis Pharmaceuticals Inc. stock beat market expectations this quarterEarnings Recap Report & Low Risk Entry Point Tips - newser.com
Can Zentalis Pharmaceuticals Inc. rally from current levelsQuarterly Portfolio Summary & Expert Curated Trade Setup Alerts - newser.com
Will Zentalis Pharmaceuticals Inc. stock keep outperforming rivals2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
How currency fluctuations impact Zentalis Pharmaceuticals Inc. stockEarnings Growth Report & Smart Investment Allocation Tips - newser.com
Can Zentalis Pharmaceuticals Inc. stock reach $100 price targetEarnings Miss & Community Driven Trade Alerts - newser.com
How Zentalis Pharmaceuticals Inc. stock benefits from strong dollarInsider Buying & Daily Entry Point Trade Alerts - newser.com
How Future Regulation Could Impact Future Lifestyle Fashions Limited ProfitabilitySector Leadership Analysis & Breakout Portfolio Performance - earlytimes.in
Multi asset correlation models including Zentalis Pharmaceuticals Inc.2025 Top Gainers & Daily Chart Pattern Signal Reports - newser.com
What recovery options are there for Zentalis Pharmaceuticals Inc.Profit Target & AI Forecast for Swing Trade Picks - newser.com
Zentalis Pharmaceuticals Stock Faces Pressure as Insider Bets Turn Negative - AD HOC NEWS
Zentalis Pharmaceuticals Slides As Insider Purchases Lose Another US$37k - simplywall.st
How to build a custom watchlist for Zentalis Pharmaceuticals Inc.2025 Price Targets & Verified Chart Pattern Trade Signals - newser.com
How Zentalis Pharmaceuticals Inc. stock performs in high volatility marketsStop Loss & Fast Gaining Stock Strategy Reports - newser.com
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
1.19%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):